Diet Drug Acomplia (Rimonabant) Gets Reprieve in Europe

Diet drug Acomplia (rimonabant) was discussed by European regulators at their June meeting this week, but the only decision reached was to discuss the matter again at their July 16-to-19 meeting.

The Committee for Medicinal...

Sanofi to Challenge German Refusal to Subsidise Acomplia

French pharmaceutical company Sanofi-Aventis has announced plans to challenge the decision of the German Health Ministry, which has denied the company's cardiovascular drug Acomplia (rimonabant) reimbursement status.

Sanofi...

If You Want Acomplia (Rimonabant), You Won't Find It Anywhere as Zimulti

In the wake of the diet drug rimonabant (Acomplia / Zimulti) debacle on June 13th, there is no need for millions of Americans eager to try Acomplia to look for it under the new name Zimulti.

Barring a miracle, rimonabant will...

Acomplia (Rimonabant) Safety Data to Be Reviewed by Europeans Next Week

Safety data for diet pill Acomplia (rimonabant) will be reviewed by the European Medicines Agency (EMEA) next week after a U.S. panel of experts unanimously recommended against allowing the diet drug to be sold in the United...

No Action as Yet on Rimonabant in Europe

The European Agency for the Evaluation of Medical Products (EMEA) did discuss the weight-loss drug rimonabant (Acomplia, Sanofi Aventis) at its June meeting held this week, but it has not reached any conclusions on whether any...